Onyx Pharmaceuticals Announces Pricing of Concurrent Offerings of Four Million Shares of Common Stock and $200 Million Principal Amount of Convertible Senior Notes
EMERYVILLE, Calif., Aug. 6 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) today announced that it has agreed to sell an aggregate of four
million shares of its common stock at a price to the public of $30.50 per share and $200 million aggregate principal amou...
China-Biotics, Inc. Applies for Four Patents on Probiotic Formulations
SHANGHAI, July 31 /PRNewswire-Asia-FirstCall/ -- China-Biotics, Inc.
(Nasdaq: CHBT ) ("China-Biotics", "the Company"), a leading Chinese firm
specializing in the manufacture, research, development, marketing and
distribution of probiotics products, today announced it has submitted
Qforma Appoints Four Executives in Sales and Field Operations
SANTA FE, N.M., June 25 /PRNewswire/ -- Qforma, an advanced analytics and predictive modeling company, today announced the appointments of four
executives to sales and field operations positions: Mark J. Grove is appointed Senior Vice President, Sales, New Business; Dean H. Kleyn advances with...
GenVault Receives Four Critical U.S. and E.U. Patent Allowances for Key Biosample Management Technologies
CARLSBAD, Calif., May 20 /PRNewswire/ -- GenVault Corporation is pleased to announce notice of allowance for four
key patents in its growing portfolio. U.S. Patent Application #10/005,415, entitled "Automated Biological Sample Archive for Storage, Retrieval & Analysis of a Large Number of Sa...
Mylan Confirms Four First-to-File Challenges
PITTSBURGH, March 26 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL ) today announced that it and/or a subsidiary have been sued in connection with four
separate "first-to-file" Abbreviated New Drug Applications (ANDA) filed with the U.S. Food and Drug Administration (FDA).
Mylan and A...
Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints
SAN DIEGO, Jan. 8 /PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics, Inc.
(Nasdaq: OREX ) today announced that the first of four
Phase 3 trials of its
lead investigational product Contrave(R) (naltrexone sustained release
(SR)/bupropion SR) met its co-primary and key secondary endpoints, sh...
NanoBio to Give Four Scientific Presentations at Upcoming National Meeting of Pharmaceutical Scientists
ANN ARBOR, Mich., Nov. 13 /PRNewswire/ -- NanoBio Corporation announced
today that it will present new data in four
presentations that detail
milestones in its clinical and preclinical development programs in
onychomycosis, acne, herpes labialis and genital herpes during the American
InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting
- Results of Phase 1 clinical studies support advancement to Phase 2 -
- Results of in-vitro study of ITMN-191 with Roche polymerase inhibitors -
BRISBANE, Calif., Sept. 24 /PRNewswire-FirstCall/ -- InterMune, Inc.
(Nasdaq: ITMN ) today announced that four
abstracts from clinical and
As personalized, genomic medicine takes off, four developing countries show the way for others
Developing countries that want the benefits of cutting-edge health care possibilities based on the genetic variation of individual citizens and sub-populations need to foster the new science at home, says a major new Canadian study published today by Nature Publishing Group.
In a special six-p...
2008 National Ergonomics Conference Schedule Announced, Features Four New Tracks of Programming and Focus on Corporate Sustainability and Productivity; Most Product Debuts in Expo's 14-Year History
NEW YORK, Sept. 17 /PRNewswire/ -- The 14th Annual National Ergonomics
Conference and Exposition (NECE) at Caesars Palace, Las Vegas, Dec. 2-5,
will feature a record number of conference sessions, and mark the debut of
four new tracks of conference programming geared toward workplace design
RiskMetrics (ISS), An Independent Proxy Advisory Firm, Recommends Voting the GOLD Card for Four of PTV's Nominees: Anderson, McInerney, Melrose, and O'Holla
RiskMetrics Further Advises Shareholders to Reject Entire Management
Slate of InSite Vision, Including the Chairman and Chief Executive Officer
AUSTIN, Texas and HOUSTON, Sept. 11 /PRNewswire/ -- PTV Sciences
("PTV"), a healthcare venture capital and growth equity firm, is pleased to
Video: New Survey Shows Three in Four School Nurses Have Students at Risk for Severe Allergic Reactions Who Do Not Bring Auto-Injectable Epinephrine to School
Parents of students with known allergies are urged to put auto-injectable epinephrine at the top of the school supplies list
SILVER SPRING, Md., Aug. 27 /PRNewswire/ -- A new survey conducted by
the National Association of School Nurses (NASN) found that 72% of school
nurses have stud...
LI-COR Adds Four New IRDye(R) Infrared Dye Antibodies to its Product Line
LINCOLN, Neb., Aug. 12 /PRNewswire/ -- LI-COR Biosciences continues to
expand its offering of IRDye infrared dye-labeled antibodies for imaging
applications. The new IRDye(R) 680 Donkey Anti-Chicken IgG, IRDye 800CW
Donkey Anti-Chicken IgG, IRDye 680 Goat Anti-Rat IgG, and IRDye 800CW Goat
Norgen Biotek Corp. Launches Four New Kits for the Purification of RNA and DNA from Plants and Fungi
THOROLD, ON, July 18 /PRNewswire/ - Norgen Biotek Corp., an innovative
Canadian biotechnology company focusing primarily on advancing powerful
tools for RNA, DNA and protein purifications, today announced the expansion
of its product offerings by launching four
new kits geared towards the
Agendia and Ferrer Announce Exclusive Agreement for Sales of Cancer Diagnostic Services in Four Major European Markets
AMSTERDAM, The Netherlands and BARCELONA, Spain, July 15
/PRNewswire-FirstCall/ -- Agendia BV and Ferrer inCode today announced an
agreement that will give Ferrer exclusive rights to sell two of Agendia's
signature cancer diagnostic services -- MammaPrint(R), a prognostic test
that uses a 70-g...
Poniard Pharmaceuticals Appoints Four New Members to Clinical Advisory Board
- Internationally Recognized Oncologists Will Offer Strategic Guidance on Picoplatin Clinical Development -
SOUTH SAN FRANCISCO, Calif., May 28 /PRNewswire-FirstCall/ -- Poniard
Pharmaceuticals, Inc. (Nasdaq: PARD ), a biopharmaceutical company focused
on oncology, today anno...
Advance Nanotech's Owlstone Subsidiary Selected as One of Four Finalists in The 2008 Royal Academy of Engineering MacRobert Awards Competition
NEW YORK, May 22 /PRNewswire-FirstCall/ -- Advance Nanotech, Inc., (OTC
Bulletin Board: AVNA), announced today that its Owlstone Nanotech Inc.
subsidiary has been selected as one of four
finalists for the 2008 Royal
Academy of Engineering MacRobert Award, the UK's premier award for
Lentigen Corporation Receives Four Research Grants From the National Institutes of Health
BALTIMORE, May 15 /PRNewswire/ -- Lentigen Corporation announced today
that it has received four
National Institutes of Health (NIH) small
business innovation research (SBIR) grants to collaborate with leading
scientists. Through these grants, Lentigen will apply its proprietary
Peregrine Pharmaceuticals Announces Four Upcoming Presentations at the American Association for Cancer Research 2008 Annual Meeting
TUSTIN, Calif., April 11 /PRNewswire-FirstCall/ -- Peregrine
Pharmaceuticals, Inc. (Nasdaq: PPHM ), a clinical stage biopharmaceutical
company developing targeted therapies for the treatment of cancer and
hepatitis C virus infection (HCV), today announced that the following
SpectraScience Strengthens Leadership Team With Four Key Hires
SAN DIEGO, Feb. 19 /PRNewswire-FirstCall/ -- SpectraScience, Inc. (OTC
Bulletin Board: SCIE), a San Diego based medical device company, today
announced that it has hired several individuals to drive its operational
growth as it moves from an R&D focus towards a revenue generating business
Raven biotechnologies to Provide Updates on Oncology Pipeline With Four AACR Presentations
- Lead Clinical Program and Two Clinical Candidates Featured -
SOUTH SAN FRANCISCO, Calif., Feb. 12 /PRNewswire/ -- Raven
biotechnologies, inc., a privately held company focused on the discovery
and development of monoclonal antibody therapeutics (MAbs) for cancer,
Remergent(R) Announces the Launch of Four New Products Pioneers of DNA Repair Expand Anti-Aging Line
FREEPORT, N.Y., Feb. 4 /PRNewswire/ -- AGI Dermatics, the
bio-pharmaceutical laboratory that pioneered DNA research for skincare will
innovative products to the Remergent line: Advanced Retinol
Therapy (1% retinol), Progressive Retinol Complex (0.4% retinol),
SDCRM Receives Highest Score in Three of Four Categories from CIRM on Part I of Major Facilities Grant Application
SAN DIEGO, Jan. 18 /PRNewswire/ -- The San Diego Consortium for
Regenerative Medicine (SDCRM) today announced that it has received the
highest score in three of four
categories from the California Institute of
Regenerative Medicine (CIRM) on Part I of the Major Facilities Grant
Micromet is Presenting Four Posters on BiTE(R) Antibodies at the International AACR-NCI-EORTC Conference
Presentation on MCSP-specific BiTE Antibody Selected by AACR for Press Coverage
BETHESDA, Md., Oct. 23 /PRNewswire-FirstCall/ -- Micromet, Inc.
(Nasdaq: MITI ), a biopharmaceutical company focusing on the development of
novel, proprietary antibody-based product...
The Pittsburgh Life Sciences Greenhouse Elects Four New Members to Its Board of Directors
PITTSBURGH, Sept. 13 /PRNewswire/ -- The Pittsburgh Life Sciences
Greenhouse (PLSG), the private/public partnership putting the region's life
sciences industry on a fast track for growth, announced that Peter M.
DeComo, Chairman and Chief Executive Officer, Renal Solutions, Inc., John
SGIs Wisconsin branch builds fastest supercomputer yet in four months
Photo courtesy of Silicon Graphics Inc. Chippewa Valley, Wis. — Silicon Graphics Inc. built the world's fastest supercomputer in about 129 days, and it was the company's Chippewa Falls, Wisconsin, plant that pulled the project together. SGI announced the completion of the $50 million p...
UW engineering career fair sees highest attendance in four years
Madison, Wis. - At least 3,600 University of Wisconsin-Madison engineering students looking to enter the job market descended on the Engineering Centers building last week for the semiannual Career Connection Fair.
Sponsored by UW-Madison's Engineering Career Services , the fair brought at ...
Novavax Reports Second Quarter 2009 Financial Results
...f 2009, the company recorded a $0.5 million unrealized gain, which is included in other comprehensive income related to the recovery of fair value for four
of the securities.
The net decrease in cash and short-term investments of $2.7 million was principally due to cash spent for operations and cas...
Kensey Nash Announces Agreement to Acquire Rights to OsseoFit Product
...romCat(TM) and SafeCross(TM) products, as well as the Company's success in distributing its products into the marketplace, the Company's dependence on four
major customers (St. Jude Medical, Arthrex, Orthovita and Spectranetics) and their success in selling Kensey Nash related products in the marketplace,...
InterMune Reports Second Quarter 2009 Financial Results and Business Highlights
...terferon or ribavirin, in patients with HCV infection. Data from the first four
dosage cohorts of the study demonstrated that the combination resulted in s... daily doses (600mg and 900mg twice daily) than those explored in the first four
Today the company announced that results of all se...
Curis and Debiopharm Sign an Exclusive License Agreement Covering the HSP90 Inhibitor CUDC-305
...ng, drug delivery and formulation, and regulatory affairs.
Founded in 1979 and headquartered in Lausanne, Switzerland, Debiopharm
has developed four
products with global combined sales in excess of $2.6
billion in 2008.
For more information on Debiopharm Group, please visit:
China Sky One Medical, Inc. Appoints New Independent Director
...ng Qi-Feng resigned from the
Board effective August 4, 2009. Following this appointment, China Sky One
Medical's Board of Directors has seven members, four
of whom are independent.
Mr. Wei Lee also replaces Mr. Jiang as a member of the Audit Committee,
Compensation Committee and Finance Committee of the B...
Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009
...d an approximately 23 percent lower restenosis rate at two years compared to the prior-generation TAXUS Express.
The Swedish registry study included four
DES brands: TAXUS Liberte, TAXUS Express, Cypher and Endeavor. In total, the registry included 35,478 DES implants during 22,962 procedures in 19,004 ...
New clues about a hydrogen fuel catalyst
...s job fairly well, but might have potential for improvement. Their initial work showed that the catalyst worked as a molecule that contained a core of four
rhodium atoms in a tetrahedron, or a triangular pyramid, with each corner decorated with boron and other elements. But the rhodium and other atoms cou...
PDI Reports 2009 Second Quarter Financial Results
...second quarter ended June 30, 2009. Recent highlights include:
new business wins expected to exceed $18 million in revenue over 12 months ...ive to build our business.
"Notably, during the quarter we announced four
key new business wins expected to exceed $18 million in revenue over 12 mon...
TSH Testing Raises Awareness of Importance of Thyroid Health
...ed since 1980," said Joseph Mangano, MPH, MBA, executive director of the Radiation and Public Health Project, sponsors of the testing program. "In the four
counties neighboring Indian Point, thyroid cancer is 70% above the U.S. rate and newborn hypothyroidism, a cause of mental retardation, is 90% greater...
Shire plc: Core Portfolio of Products Delivers 20% Sales Growth
...owth prospects. We continue to
increase the global reach of our business, and now have a presence in 26
countries worldwide compared to nine countries four
We have also developed a promising pipeline with encouraging recent news.
With the receipt of a Complete Response Letter from the US...
Pharmacyclics, Inc. Rights Offering Oversubscribed
..., differentiated products that have the potential to significantly improve the standard of care in the markets it serves. Presently, Pharmacyclics has four
product candidates in clinical development and two product candidates in pre-clinical development. It is Pharmacyclics' business strategy to establish...
Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results
...with fidaxomicin experienced a reduction in CDI recurrence compared to Vancocin (p=0.004) and had a higher global cure (cure with no recurrence within four
weeks) compared to Vancocin (p=0.006).
Clinical investigator, Mark A. Miller, M.D., presented additional data from Optimer's fidaxomicin North A...
Saint-Gobain Introduces Next Generation Silicone Tubing
...and Pure-Fit are just a few of the many well-known brands in the company's portfolio.
About Saint-Gobain Performance Plastics
For more than four
decades, Saint-Gobain Performance Plastics and its family of companies have supplied the world with innovative, high-performance polymer products for ...